Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Cash from Financing Activities for 2 consecutive years, with $1000.0 as the latest value for Q2 2025.

  • Quarterly Cash from Financing Activities fell 99.92% to $1000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $15000.0 through Dec 2025, down 99.99% year-over-year, with the annual reading at $15000.0 for FY2025, 99.99% down from the prior year.
  • Cash from Financing Activities hit $1000.0 in Q2 2025 for Silence Therapeutics, down from $14000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $133.0 million in Q1 2024 to a low of -$98000.0 in Q4 2024.